Colangitis esclerosante asociada a infección severa por SARS-CoV-2
DOI:
https://doi.org/10.52784/27112330.161Palabras clave:
SARS-CoV-2, colangitis esclerosante secundaria, enfermedad crítica, COVID-19, ácido ursodesoxicólico, trasplante.Resumen
La colangitis esclerosante secundaria es una enfermedad poco prevalente, de etiología multifactorial y con una fisiopatología progresiva, caracterizada por obstrucción biliar y fibrosis. Entre las múltiples causas se destacan las siguientes: inmunomediada por IgG4, isquémica, infecciosa y relacionada a medicamentos. En el contexto de la pandemia por SARS-CoV-2, se han reportado algunas series de casos que determinan una asociación entre estas dos entidades. Se presenta el caso de una mujer en la octava década de la vida con infección por SARS-CoV-2 grave, que cursó con ictericia progresiva, perfil hepático con patrón colestásico, y hallazgos imagenológicos de colangitis esclerosante con vía biliar desestructurada de manera difusa, microcálculos y barro biliar. Se diagnosticó colangitis esclerosante secundaria a SARS-CoV-2 y se dio manejo con ácido ursodesoxicólico.
Descargas
Referencias bibliográficas
Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-NCOV infection. bioRxiv 2020. https://doi.org/10.1101/2020.02.03.931766.
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020;73:566-574. https://doi.org/10.1016/j.jhep.2020.04.006.
Martins P, Verdelho Machado M. Secondary sclerosing cholangitis in critically ill patients: An underdiagnosed entity. GE Port J Gastroenterol 2020;27:103-114. https://doi.org/10.1159/000501405.
Bütikofer S, Lenggenhager D, Wendel Garcia PD, Maggio EM, Haberecker M, Reiner CS, et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver international : official journal of the International Association for the Study of the Liver 2021;41:2404-2417. https://doi.org/10.1111/liv.14971.
Leonhardt S, Veltzke-Schlieker W, Adler A, Schott E, Hetzer R, Schaffartzik W, et al. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit Care 2015;19:131. https://doi.org/10.1186/s13054-015-0861-5.
Lin T, Qu K, Xu X, Tian M, Gao J, Zhang C, et al. Sclerosing cholangitis in critically ill patients: an important and easily ignored problem based on a German experience. Front Med 2014;8:118-126. https://doi.org/10.1007/s11684-014-0306-6.
Kirchner GI, Rümmele P. Update on sclerosing cholangitis in critically ill patients. Viszeralmedizin 2015;31:178-184. https://doi.org/10.1159/000431031.
Weig T, Schubert MI, Gruener N, Dolch ME, Frey L, Miller J, et al. Abdominal obesity and prolonged prone positioning increase risk of developing sclerosing cholangitis in critically ill patients with influenza A-associated ARDS. Eur J Med Res 2012;17:30. https://doi.org/10.1186/2047-783x-17-30.
Chanques G, Constantin JM, Devlin JW, Ely EW, Fraser GL, Gélinas C, et al. Analgesia and sedation in patients with ARDS. Intensive Care Med 2020;46:2342-2356. https://doi.org/10.1007/s00134-020-06307-9.
Keta-Cov research group. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol 2021;74:1243-1244. https://doi.org/10.1016/j.jhep.2021.02.007.
Gudnason HO, Björnsson ES. Secondary sclerosing cholangitis in critically ill patients: current perspectives. Clin Exp Gastroenterol 2017;10:105-111. https://doi.org/10.2147/CEG.S115518.
Klindt C, Jensen B-E, Brandenburger T, Feldt T, Killer A, Schimmöller L, et al. Secondary sclerosing cholangitis as a complication of severe COVID-19: A case report and review of the literature. Clin Case Rep 2021;9:e04068. https://doi.org/10.1002/ccr3.4068.
Edwards K, Allison M, Ghuman S. Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Reports 2020;13:e237984. https://doi.org/10.1136/bcr-2020-237984.
Esposito I, Kubisova A, Stiehl A, Kulaksiz H, Schirmacher P. Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis. Virchows Arch 2008;453:339-345. https://doi.org/10.1007/s00428-008-0654-1.
Roth NC, Kim A, Vitkovski T, Xia J, Ramirez G, Bernstein D, et al. Post-COVID-19 cholangiopathy: A novel entity. Am J Gastroenterol 2021;116:1077-1082. https://doi.org/10.14309/ajg.0000000000001154.
Gelbmann CM, Rümmele P, Wimmer M, Hofstädter F, Göhlmann B, Endlicher E, et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol 2007;102:1221-1229. https://doi.org/10.1111/j.1572-0241.2007.01118.x.
Reichert MC, Jüngst C, Grünhage F, Lammert F, Krawczyk M. Secondary sclerosing cholangitis rapidly leading to liver cirrhosis: a possible post-ICU treatment sequel. QJM 2015;109:119-120. https://doi.org/10.1093/qjmed/hcv119.
Jaeger C, Mayer G, Henrich R, Gossner L, Rabenstein T, May A, et al. Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: clinical presentation, endoscopic findings, treatment, and follow-up. Endoscopy 2006;38:730-734. https://doi.org/10.1055/s-2006-925241.
Kwon ON, Cho SH, Park CK, Mun SH. Biliary cast formation with sclerosing cholangitis in critically ill patient: case report and literature review. Korean J Radiol 2012;13:358-362. https://doi.org/10.3348/kjr.2012.13.3.358.
Lee A, Wein AN, Doyle MBM, Chapman WC. Liver transplantation for post-COVID-19 sclerosing cholangitis. BMJ Case Rep 2021;14:e244168. https://doi.org/10.1136/bcr-2021-244168.
Durazo FA, Nicholas AA, Mahaffey JJ, Sova S, Evans JJ, Trivella JP, et al. Post-COVID-19 cholangiopathy-a new indication for liver transplantation: A case report. Transplant Proc 2021;53:1132-1137. https://doi.org/10.1016/j.transproceed.2021.03.007.
Meersseman P, Blondeel J, De Vlieger G, van der Merwe S, Monbaliu D. Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients. Intensive Care Med 2021;47:1037-1040. https://doi.org/10.1007/s00134-021-06445-8.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
